Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Jinxin Tao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7760-6607; OpenAlex author ID A5040458704. Sources: OpenAlex.

Their work

Papers
18 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 5 papers · 2024: 6 papers · 2025: 2 papers · 2026: 1 paper

Papers 18

  1. Integrated scRNA-Seq and functional profiling reveal CD52 as a driver of pancreatic ductal adenocarcinoma metastasis and immunosuppression. First author DOI 10.1038/s41389-026-00637-x↗
  2. SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocarcinoma Tumor Microenvironment. Co-author DOI 10.1002/mc.23936↗
  3. Decipher the single-cell level responses to chemotherapy in pancreatic ductal adenocarcinoma by a cross-time context graph model. Co-author DOI 10.1016/j.canlet.2025.217751↗
  4. E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradation. Co-author DOI 10.1016/j.freeradbiomed.2024.05.031↗
  5. The NF-κB/NUAK2 signaling axis regulates pancreatic cancer progression by targeting SMAD2/3. Co-author DOI 10.1016/j.isci.2024.109406↗
  6. Multiomics integration reveals NETosis heterogeneity and TLR2 as a prognostic biomarker in pancreatic cancer. First author DOI 10.1038/s41698-024-00586-x↗
  7. FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis. Co-author DOI 10.1158/0008-5472.can-23-3638↗
  8. Unbiasedly decoding the tumor microenvironment with single-cell multiomics analysis in pancreatic cancer. First author DOI 10.1186/s12943-024-02050-7↗
  9. CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. Co-author DOI 10.1186/s13046-024-03201-w↗
  10. Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer. Co-author DOI 10.1007/s13402-023-00836-3↗
  11. Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. Co-author DOI 10.1016/j.canlet.2023.216423↗
  12. PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway. Co-author DOI 10.1016/j.heliyon.2023.e17194↗
  13. Using a microRNA panel of circulating exosomes for diagnosis of pancreatic cancer: multicentre case-control study. Co-author DOI 10.1093/bjs/znac375↗
  14. Epidemiology of pancreatic cancer: New version, new vision. Co-author DOI 10.21147/j.issn.1000-9604.2023.05.03↗
  15. HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway. Co-author DOI 10.1002/mc.23420↗
  16. Targeting hypoxic tumor microenvironment in pancreatic cancer. Co-author DOI 10.1186/s13045-020-01030-w↗
  17. Identification and Validation of Constructing the Prognostic Model With Four DNA Methylation-Driven Genes in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.709669↗
  18. Current epidemiology of pancreatic cancer: Challenges and opportunities. First author DOI 10.21147/j.issn.1000-9604.2020.06.04↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taiping Zhang · 18 shared papers, 2020–2026 · strength 3.20
  2. Wenhao Luo · 10 shared papers, 2020–2025 · strength 1.79
  3. Yueze Liu · 10 shared papers, 2022–2025 · strength 1.78
  4. Jiangdong Qiu · 9 shared papers, 2023–2025 · strength 1.63
  5. Gang Yang · 8 shared papers, 2021–2025 · strength 1.31
  6. Jiangdong Qiu · 7 shared papers, 2021–2025 · strength 1.16
  7. Guangyu Chen · 7 shared papers, 2021–2025 · strength 1.13
  8. Ruobing Wang · 6 shared papers, 2023–2024 · strength 1.12
  9. Yupei Zhao · 7 shared papers, 2021–2024 · strength 1.11
  10. Dan Su · 6 shared papers, 2022–2024 · strength 1.03
  11. Yifan Fu · 5 shared papers, 2024–2026 · strength 0.99
  12. Fangyu Zhao · 6 shared papers, 2021–2023 · strength 0.91
  13. Lei You · 5 shared papers, 2021–2025 · strength 0.79
  14. Zhe Cao · 4 shared papers, 2023–2026 · strength 0.76
  15. Tao Liu · 4 shared papers, 2024–2025 · strength 0.74
  16. Hua Huang · 4 shared papers, 2023–2025 · strength 0.71
  17. Jun Wang · 3 shared papers, 2023–2025 · strength 0.53
  18. Jianchun Xiao · 3 shared papers, 2023–2025 · strength 0.52
  19. Yuanyang Wang · 2 shared papers, 2024–2025 · strength 0.39
  20. Dan Su · 2 shared papers, 2024 · strength 0.39
  21. Wenhao Luo · 2 shared papers, 2023–2024 · strength 0.35
  22. Dan Su · 2 shared papers, 2024 · strength 0.35
  23. Yuanyang Wang · 1 shared paper, 2026 · strength 0.25
  24. Zeyu Zhang · 1 shared paper, 2026 · strength 0.25
  25. Bo Xu Ren · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.